Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Albendazole and/or Vitamin a · 1 trial · 3 indications
| Name | Type | Description |
|---|---|---|
| Albendazole (400 mg) and/or Vitamin a | DRUG | - |
Inclusion Criteria: * Local residents * Aged 1-5 years * Informed written parental consent Exclusion Criteria: * Refusal to give consent * prior enrollment in the study
Albendazole and/or Vitamin A is being studied for use in malnutrition, specifically in children under five years of age with worm infestation. The investigational treatment is in Phase 3 clinical development for this metabolic condition.
United Therapeutics Corporation (NASDAQ: UTHR) is the developer of Albendazole and/or Vitamin A. The company is conducting clinical research on this combination for the treatment of malnutrition in young children.
Albendazole and/or Vitamin A is in Phase 3 clinical development. It is an investigational small molecule treatment for malnutrition and has not been approved by regulatory authorities. The Phase 3 trial has been completed.
Albendazole and/or Vitamin A was studied in the clinical trial NCT00396500, titled "Deworming and Vitamin A (DEVTA) Prepilot Study." This Phase 3 trial enrolled 4,000 participants in India and has been completed.
The Phase 3 trial of Albendazole and/or Vitamin A was randomized but not double-blind, and it used an uncontrolled design. The study enrolled 4,000 participants aged one year and older, including both males and females.